CFZ studies that include ORR data
| Study . | Phase . | Cohort . | CFZ regimen . | CFZ dosage . | ORR (> PR) . |
|---|---|---|---|---|---|
| PX 171-001 | 1 | C in relapsed hematological malignancies | 5 consecutive days 2-wk cycle | 11-15 mg/m2 | 10% |
| PX-171-002 | 1 | C in relapsed hematological malignancies | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2; step up: 1st cycle: 20 mg/m2 all following cycles: 27 mg/m2 | 19% |
| PX-171-003-A0 | 2 | C in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 20 mg/m2 | 17% |
| PX-171-003-A1 | 2 | C in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 24% |
| PX-171-004-A0 | 2 | C in relapsed, refractory MM, BTZ naive | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 42%/52% |
| PX-171-004-A1 | 2 | C in relapsed, refractory MM, BTZ pretreated | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 17% |
| PX-171-005 | 2 | C in relapsed, refractory MM with renal impairment | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2 | 21% |
| PX-171-006 | 1b | CRd in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2 | 78% |
| PX-171-007 | 1b/2 | C in relapsed, refractory MM and other malignancies | 2×/7d × 3 wks, 4-wk cycle | 20-70 mg/m2, extended infusion time (30 minutes) | 60% |
| NCT01029054 | 1/2 | CRd in de novo MM | 2×/7d × 3 wks, 4-wk cycle | 20/27/36 mg/m2 | 98% |
| NCT01057225 (CYCLONE) | 1/2 | CCyTd de novo MM | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2 (step up) | 100% |
| Study . | Phase . | Cohort . | CFZ regimen . | CFZ dosage . | ORR (> PR) . |
|---|---|---|---|---|---|
| PX 171-001 | 1 | C in relapsed hematological malignancies | 5 consecutive days 2-wk cycle | 11-15 mg/m2 | 10% |
| PX-171-002 | 1 | C in relapsed hematological malignancies | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2; step up: 1st cycle: 20 mg/m2 all following cycles: 27 mg/m2 | 19% |
| PX-171-003-A0 | 2 | C in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 20 mg/m2 | 17% |
| PX-171-003-A1 | 2 | C in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 24% |
| PX-171-004-A0 | 2 | C in relapsed, refractory MM, BTZ naive | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 42%/52% |
| PX-171-004-A1 | 2 | C in relapsed, refractory MM, BTZ pretreated | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2, (step up) | 17% |
| PX-171-005 | 2 | C in relapsed, refractory MM with renal impairment | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2 | 21% |
| PX-171-006 | 1b | CRd in relapsed, refractory MM | 2×/7d × 3 wks, 4-wk cycle | 15-27 mg/m2 | 78% |
| PX-171-007 | 1b/2 | C in relapsed, refractory MM and other malignancies | 2×/7d × 3 wks, 4-wk cycle | 20-70 mg/m2, extended infusion time (30 minutes) | 60% |
| NCT01029054 | 1/2 | CRd in de novo MM | 2×/7d × 3 wks, 4-wk cycle | 20/27/36 mg/m2 | 98% |
| NCT01057225 (CYCLONE) | 1/2 | CCyTd de novo MM | 2×/7d × 3 wks, 4-wk cycle | 20/27 mg/m2 (step up) | 100% |
C indicates CFZ; R, revlimid; d, low-dose dexamethasone; and T, thalidomide.